

HETEROCYCLES, Vol. 94, No. 8, 2017, pp. 1427 - 1438. © 2017 The Japan Institute of Heterocyclic Chemistry
Received, 13th April, 2017, Accepted, 8th June, 2017, Published online, 13th June, 2017
DOI: 10.3987/COM-17-13720

**SYNTHESIS OF 7,8-DIHYDROPYRIDO[2,3-*d*]PYRIMIDINE
DERIVATIVES FROM 4,6-DICHLORO-2-
(METHYLSULFANYL)PYRIMIDINE**

**Kazuhiro Kobayashi,^{a*} Ippei Nozawa,^a Takuma Ueyama,^a Hiroaki Utsumi,^a
Hidetaka Hiyoshi,^b and Kazuto Umezu^b**

^a Applied Chemistry Field, Chemistry and Biotechnology Course, Department of Engineering, Graduate School of Sustainability Science, Tottori University, 4-101 Koyama-minami, Tottori 680-8552, Japan; E-mail: kkoba@chem.tottori-u.ac.jp ^b Ihara Chemical Industry Co., Ltd., Development Sect., Marketing and Development Dept., Marketing Division, 4-26 Ikenohata 1-chome, Taito-ku, Tokyo 110-0008; E-mail: kazuto.umezu@iharachem.co.jp

Abstract – A new and convenient method for the preparation of 7,8-dihydropyrido[2,3-*d*]pyrimidine derivatives has been developed utilizing a three-step sequence starting with a commercially available 4,6-dichloro-2-(methylsulfanyl)pyrimidine (DCSMP). Thus, successive treatment of the starting material with LDA and cinnamaldehyde or its derivatives leads to the formation of 3-aryl-1-[4,6-dichloro-2-(methylsulfanyl)pyrimidin-5-yl]prop-2-en-1-ols. After replacement of one of the two chloro-substituents with primary amines, cyclization of the resulting precursors gives the desired products on treatment with methanesulfonyl chloride in the presence of triethylamine.

INTRODUCTION


A number of 7,8-dihydropyrido[2,3-*d*]pyrimidine derivatives have recently been synthesized, and most of them have been shown to exhibit a wide variety of biological activities.¹ Therefore, some methods for the general preparation of these derivatives has been developed.² Liu *et al.* have reported the synthesis by the reaction of α -alkenoyl- α -carbamoyl ketene-*S,S*-acetals with ammonium acetate followed by annulation with excessive Vilsmeier reagent.^{2a} The synthesis by three-component condensation of 5-acetyl-4-aminopyrimidines, cyclohexane-1,3-diones, and orthocarboxylic acid esters has been reported by Dorokhov *et al.*^{2b} These methods, however, have defects such as limited scope and somewhat harsh

reaction conditions. In a continuation of our studies on the syntheses of pyrimidine-fused heterocyclic derivatives utilizing 4,6-dichloro-2-(methylsulfanyl)pyrimidine (DCSMP) (**1**) as a starting material,³ we now wish to report an efficient three-step procedure for the preparation of a new type of 7,8-dihydropyrido[2,3-*d*]pyrimidine derivatives, 8-alkyl-7-aryl-4-chloro-2-(methylsulfanyl)-7,8-dihydropyrido[2,3-*d*]pyrimidines (**4**) from **1**, which can be conducted under mild conditions.

RESULTS AND DISCUSSION

Our three-step synthesis of **4** from commercially available **1** was conducted according to the sequence outlined in Scheme 1. Thus, the starting material (**1**) was lithiated at the 5-position with LDA in THF at $-78\text{ }^{\circ}\text{C}$ to generate 4,6-dichloro-5-lithio-2-(methylsulfanyl)pyrimidine,^{3a} which was allowed to react with cinnamaldehyde and its derivatives to give the corresponding 3-aryl-1-[4,6-dichloro-2-(methylsulfanyl)pyrimidin-5-yl]prop-2-en-1-ols (**2**) in good yields, as shown in Scheme 1. Replacement of one of the two chloro-substituents of **2** with primary amines proceeded relative smoothly and cleanly in DMF at room temperature in the presence of triethylamine to provide 1-[4-(alkylamino)-6-chloro-2-(methylsulfanyl)pyrimidin-5-yl]-3-arylprop-2-en-1-ols (**3**) in generally good to excellent yields, as summarized in Table 1.

Subsequent cyclization of compounds **3**, thus obtained, using an equivalent each of methanesulfonyl chloride and triethylamine in THF proceeded quickly at $0\text{ }^{\circ}\text{C}$. After aqueous workup and the subsequent purification by column chromatography on silica gel or recrystallization, the desired 7,8-dihydropyrido[2,3-*d*]pyrimidine derivatives (**4**) were obtained, albeit in generally moderate yields, as compiled in Table 1 as well.




Scheme 1

Table 1. Preparation of 7,8-dihydropyrido[2,3-*d*]pyrimidines (**4**)

Entry	2	R in RNH ₂	3	Yield/% ^a	4	Yield/% ^a
1	2a (Ar = Ph)	<i>n</i> -Bu	3a	79	4a	64
2	2a	Bn	3b	84	4b	52
3	2a	MeO(CH ₂) ₂	3c	74	4c	85
4	2b (Ar = 4-MeC ₆ H ₄)	Me	3d	93	4d	51
5	2b	3,4-Cl ₂ C ₆ H ₃ CH ₂	3e	91	4e	48
6	2c (Ar = 4-ClC ₆ H ₄)	Me	3f	93	4f	43
7	2c	Ph(CH ₂) ₂	3g	91	4g	45
8	2d (Ar = 4-MeOC ₆ H ₄)	Me	3h	72	4h	66
9	2d	Bn	3i	61	4i	52
10	2d	4-ClC ₆ H ₄ CH ₂	3j	53	4j	59
11	2d	cyclopropyl	3k	69	4k	54

^a Yields of isolated products.

In order to expand the synthetic potential of the present methodology, attempts at the use of 2-aminoacetonitrile as a primary amine were carried out. Thus, compounds (**2b**) and (**2d**) were allowed to react with 2-aminoacetonitrile hydrochloride in DMF in the presence of two equivalents of triethylamine at room temperature. We have found that this amine was much less reactive than the other primary amines used in this study, and the reactions proceeded very slowly to give (cyanomethyl)amino products (**5b**) and (**5d**), respectively, only in moderate yields. However, transformation of these compounds into the corresponding 7,8-dihydropyrido[2,3-*d*]pyrimidine derivatives (**6b**) and (**6d**) proceeded very cleanly and rapidly with high yields under the same conditions as described for the preparation of **4**, as shown in Scheme 2.

**Scheme 2**

It is noteworthy that an attempt to obtain 7,8-dimethyl-7,8-dihydropyrido[2,3-*d*]pyrimidine from the respective precursor, prepared similarly from DCSMP, crotonaldehyde and methylamine, under the same conditions as described above was unsuccessful. The reaction gave an intractable mixture of products. The expected product may be too unstable to survive under the reaction conditions.

In conclusion, we have developed a convenient method for the preparation of 8-alkyl-7-aryl-7,8-dihydropyrido[2,3-*d*]pyrimidine derivatives. The present method may be of value in organic synthesis because of the ease of operations, as well as the ready availability of the starting materials, and it may

offer the possibility to access compounds of potential biological importance through further functionalization at the 2- and 4-positions.

EXPERIMENTAL

All melting points were obtained on a Laboratory Devices MEL-TEMP II melting apparatus and are uncorrected. IR spectra were recorded with a Perkin–Elmer Spectrum 65 FTIR spectrophotometer. ^1H NMR and ^{13}C NMR spectra were recorded using TMS as an internal reference with a Bruker Biospin AVANCE II 600 spectrometer operating at 600 MHz and 150 MHz, respectively, or a JEOL ECP500 FT NMR spectrometer operating at 500 and 125 MHz, respectively. High-resolution MS spectra were measured by a Thermo Scientific Exactive spectrometer (ESI, positive) or a JEOL JMS-T100GCV (EI, TOF; 70 eV) spectrometer. Elemental analyses were performed with an Elementar Vario EL II instrument. TLC was carried out on Merck Kieselgel 60 PF₂₅₄. Column chromatography was performed using WAKO GEL C-200E. All of the organic solvents used in this study were dried over appropriate drying agents and distilled prior to use.

Starting Materials. *n*-BuLi was supplied by Asia Lithium Corporation. All other chemicals used in this study were commercially available.

Typical Procedure for the Preparation of 3-Aryl-1-[4,6-dichloro-2-(methylsulfanyl)pyrimidin-5-yl]prop-2-en-1-ols (2). **1-[4,6-Dichloro-2-(methylsulfanyl)pyrimidin-5-yl]-3-phenylprop-2-en-1-ol (2a).** To a stirred solution of LDA (10 mmol), generated from *i*-Pr₂NH and *n*-BuLi by the standard method, in THF (15 mL) at $-78\text{ }^\circ\text{C}$ was added a solution of **1** (0.97 g, 5.0 mmol) in THF (5 mL) dropwise. After 30 min, (*E*)-PhCH=CHCHO (0.66 g, 5.0 mmol) was added and stirring was continued for an additional 10 min before addition of saturated aqueous NH₄Cl (30 mL). The mixture was warmed to rt and extracted with AcOEt (3 × 20 mL). The combined extracts were washed with brine (20 mL), dried (Na₂SO₄), and concentrated by evaporation. The residue was purified by column chromatography on SiO₂ to give **2a** (1.5 g, 93%); a pale-yellow oil; *R*_f 0.25 (AcOEt/hexane 1:6); IR (neat) 3438, 1646 cm⁻¹; ^1H NMR (500 MHz, CDCl₃) δ 2.58 (s, 3H), 2.77 (d, *J* = 9.2 Hz, 1H), 5.97 (dd, *J* = 9.2, 6.3 Hz, 1H), 6.50 (dd, *J* = 16.0, 6.3 Hz, 1H), 6.67 (d, *J* = 16.0 Hz, 1H), 7.27 (t, *J* = 7.4 Hz, 1H), 7.33 (t, *J* = 7.4 Hz, 2H), 7.39 (d, *J* = 7.4 Hz, 2H); ^{13}C NMR (125 MHz, CDCl₃) δ 14.41, 70.46, 125.80, 126.40, 126.68, 128.30, 128.66, 132.67, 135.78, 160.37, 172.12. Anal. Calcd for C₁₄H₁₂Cl₂N₂OS: C, 51.39; H, 3.70; N, 8.56. Found: C, 51.40; H, 3.79; N, 8.42.

1-[4,6-Dichloro-2-(methylsulfanyl)pyrimidin-5-yl]-3-(4-methylphenyl)prop-2-en-1-ol (2b): a white solid; mp 108–111 °C (hexane/CH₂Cl₂); IR (KBr) 3413, 1646, 1611 cm⁻¹; ^1H NMR (600 MHz, CDCl₃) δ 2.34 (s, 3H), 2.57 (s, 3H), 2.75 (d, *J* = 8.4 Hz, 1H), 5.94–5.96 (m, 1H), 6.45 (dd, *J* = 16.2, 6.0 Hz, 1H), 6.63 (dd, *J* = 16.2, 1.2 Hz, 1H), 7.13 (d, *J* = 7.8 Hz, 2H), 7.28 (d, *J* = 7.8 Hz, 2H); ^{13}C NMR (150 MHz,

CDCl₃) δ 14.44, 21.25, 70.67, 125.33, 125.94, 126.66, 129.41, 132.79, 133.04, 138.36, 160.40, 172.10. Anal. Calcd for C₁₅H₁₄Cl₂N₂OS: C, 52.80; H, 4.14; N, 8.21. Found: C, 52.87; H, 4.22; N, 8.05.

3-(4-Chlorophenyl)-1-[4,6-dichloro-2-(methylsulfanyl)pyrimidin-5-yl]prop-2-en-1-ol (2c): a white solid; mp 132–135 °C (hexane/CH₂Cl₂); IR (KBr) 3415 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 2.50 (s, 3H), 2.75 (d, J = 8.0 Hz, 1H), 5.89 (dd, J = 8.0, 6.3 Hz, 1H), 6.40 (dd, J = 15.5, 6.3 Hz, 1H), 6.56 (d, J = 15.5 Hz, 1H), 7.22 (d, J = 9.2 Hz, 2H), 7.23 (d, J = 9.2 Hz, 2H); ¹³C NMR (125 MHz, CDCl₃) δ 14.42, 70.33, 125.57, 127.09, 127.89, 128.85, 131.38, 133.99, 134.28, 160.35, 172.30. Anal. Calcd for C₁₄H₁₁Cl₃N₂OS: C, 46.49; H, 3.07; N, 7.75. Found: C, 46.62; H, 3.17; N, 7.73.

1-[4,6-Dichloro-2-(methylsulfanyl)pyrimidin-5-yl]-3-(4-methoxyphenyl)prop-2-en-1-ol (2d): a pale-yellow oil; R_f 0.30 (AcOEt/hexane 1:3); IR (neat) 3411, 1607 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 2.57 (s, 3H), 2.77 (d, J = 8.6 Hz, 1H), 3.81 (s, 3H), 5.94 (ddd, J = 8.6, 6.3, 1.7 Hz, 1H), 6.39 (ddd, J = 16.0, 8.6, 1.7 Hz, 1H), 6.61 (d, J = 16.0 Hz, 1H), 6.86 (d, J = 8.6 Hz, 2H), 7.32 (d, J = 8.6 Hz, 2H); ¹³C NMR (125 MHz, CDCl₃) δ 14.40, 55.29, 70.72, 114.08, 124.00, 125.97, 127.98, 128.51, 132.45, 159.76, 160.33, 171.99. MR-MS (EI). Calcd for C₁₅H₁₄Cl₂N₂O₂S (M): 356.0153. Found: m/z 356.0153.

Typical Procedure for the Preparation of 1-[4-(Alkylamino)pyrimidin-5-yl]-3-phenylprop-2-en-1-ols (3). **1-[4-Butylamino-6-chloro-2-(methylsulfanyl)pyrimidin-5-yl]-3-phenylprop-2-en-1-ol (3a).** To a stirred solution of **2a** (0.44 g, 1.3 mmol) in DMF (3 mL) containing Et₃N (0.14 g, 1.3 mmol) at 0 °C was added *n*-BuNH₂ (98 mg, 1.3 mmol) dropwise and stirring was continued for 1.5 h at the same temperature. Water (20 mL) was added and the mixture was extracted with AcOEt (3 \times 10 mL). The combined extracts were washed with H₂O (3 \times 10 mL) and brine (10 mL), dried (Na₂SO₄), and concentrated by evaporation. The residue was purified by column chromatography on SiO₂ to afford **3a** (0.39 g, 79%); a yellow oil; R_f 0.20 (CH₂Cl₂); IR (neat) 3367, 1644, 1567 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 0.88 (t, J = 7.6 Hz, 3H), 1.32–1.36 (m, 2H), 1.52–1.57 (m, 2H), 2.50 (s, 3H), 2.65 (d, J = 2.3 Hz, 1H), 3.40–3.44 (m, 1H), 3.50–3.53 (m, 1H), 5.96 (br s, 1H), 6.30 (dd, J = 15.3, 4.6 Hz, 1H), 6.67–6.70 (m, 2H), 7.25 (t, J = 7.6 Hz, 1H), 7.32 (t, J = 7.6 Hz, 2H), 7.37 (d, J = 7.6 Hz, 2H); ¹³C NMR (125 MHz, CDCl₃) δ 13.72, 14.07, 20.11, 31.21, 40.82, 70.32, 108.29, 126.25, 126.59, 127.93, 128.56, 131.00, 136.15, 155.15, 160.59, 170.28. MR-MS (EI). Calcd for C₁₈H₂₂ClN₃OS (M): 363.1172. Found: m/z 363.1158.

1-{6-Chloro-2-(methylsulfanyl)-4-[(phenylmethyl)amino]pyrimidin-5-yl}-3-phenylprop-2-en-1-ol (3b): colorless needles; mp 125–127 °C (hexane/CH₂Cl₂); IR (KBr) 3382, 3279, 1659, 1574 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 2.44 (s, 3H), 3.08 (br s, 1H), 4.57 (dd, J = 15.3, 4.6 Hz, 1H), 4.78 (dd, J = 15.3, 6.1 Hz, 1H), 5.96–5.97 (m, 1H), 6.31 (dd, J = 16.1, 5.4 Hz, 1H), 6.66 (dd, J = 16.1, 1.5 Hz, 1H), 7.11 (br t, J = 5.4 Hz, 1H), 7.21–7.27 (m, 6H), 7.30–7.34 (m, 4H); ¹³C NMR (125 MHz, CDCl₃) δ 14.08, 44.91, 70.21, 108.64, 126.44, 126.62, 127.15, 127.29, 127.92, 128.53, 128.55, 130.88, 136.10, 138.47,

155.38, 160.53, 170.35. Anal. Calcd for $C_{21}H_{20}ClN_3OS$: C, 63.39; H, 5.07; N, 10.56. Found: C, 63.12; H, 4.99; N, 10.49.

1-{6-Chloro-4-[(2-methoxyethyl)amino]-2-(methylsulfanyl)pyrimidin-5-yl}-3-phenylprop-2-en-1-ol (3c): a white solid; mp 100–102 °C (hexane/ CH_2Cl_2); IR (KBr) 3324, 3236, 1583 cm^{-1} ; 1H NMR (500 MHz, $CDCl_3$) δ 2.49 (s, 3H), 2.58 (br s, 1H), 3.29 (s, 3H), 3.45–3.49 (m, 1H), 3.53–3.57 (m, 1H), 3.60–3.66 (m, 1H), 3.68–3.74 (m, 1H), 5.96 (d, $J = 5.3$ Hz, 1H), 6.33 (dd, $J = 16.0, 5.3$ Hz, 1H), 6.72 (d, $J = 16.0$ Hz, 1H), 6.98 (br s, 1H), 7.25 (t, $J = 7.6$ Hz, 1H), 7.31 (t, $J = 7.6$ Hz, 2H), 7.37 (d, $J = 7.6$ Hz, 2H); ^{13}C NMR (125 MHz, $CDCl_3$) δ 14.11, 40.72, 58.76, 70.47, 70.81, 108.53, 126.16, 126.62, 127.94, 128.56, 131.10, 136.16, 155.48, 160.51, 170.33. Anal. Calcd for $C_{17}H_{20}ClN_3O_2S$: C, 55.81; H, 5.51; N, 11.49. Found: C, 55.81; H, 5.46; N, 11.41.

1-{6-Chloro-4-(methylamino)-2-(methylsulfanyl)pyrimidin-5-yl}-3-(4-methylphenyl)prop-2-en-1-ol (3d): a white solid; mp 152–154 °C (hexane/ CH_2Cl_2); IR (KBr) 3379, 1568 cm^{-1} ; 1H NMR (600 MHz, $CDCl_3$) δ 2.32 (s, 3H), 2.51 (s, 3H), 2.99 (d, $J = 5.0$ Hz, 3H), 3.19 (s, 1H), 5.90 (d, $J = 5.5$ Hz, 1H), 6.24 (dd, $J = 16.0, 5.0$ Hz, 1H), 6.62 (dd, $J = 16.0, 1.0$ Hz, 1H), 6.76 (q, $J = 5.0$ Hz, 1H), 7.11 (d, $J = 8.0$ Hz, 2H), 7.26 (d, $J = 8.0$ Hz, 2H); ^{13}C NMR (150 MHz, $CDCl_3$) δ 14.11, 21.23, 28.13, 70.70, 108.70, 125.03, 126.60, 129.32, 131.26, 133.33, 137.99, 155.14, 161.18, 170.33. Anal. Calcd for $C_{16}H_{18}ClN_3OS$: C, 57.22; H, 5.40; N, 12.51. Found: C, 56.99; H, 5.35; N, 12.21.

1-{6-Chloro-4-[(3,4-dichlorophenyl)methyl]amino}-2-(methylsulfanyl)pyrimidin-5-yl}-3-(4-methylphenyl)prop-2-en-1-ol (3e): a white solid; mp 123–126 °C (hexane/ CH_2Cl_2); IR (KBr) 3356, 1578 cm^{-1} ; 1H NMR (600 MHz, $CDCl_3$) δ 2.34 (s, 3H), 2.42 (s, 3H), 3.09 (d, $J = 2.0$ Hz, 1H), 4.52 (dd, $J = 15.4, 5.9$ Hz, 1H), 4.73 (dd, $J = 15.4, 5.9$ Hz, 1H), 5.95 (dd, $J = 5.2, 1.1$ Hz, 1H), 6.25 (dd, $J = 16.0, 5.2$ Hz, 1H), 6.62 (dd, $J = 16.0, 1.1$ Hz, 1H), 7.06 (dd, $J = 8.2, 2.0$ Hz, 1H), 7.13 (d, $J = 8.0$ Hz, 2H), 7.15 (t, $J = 5.9$ Hz, 1H), 7.24 (d, $J = 8.0$ Hz, 2H), 7.25 (d, $J = 8.2$ Hz, 1H), 7.34 (d, $J = 2.0$ Hz, 1H); ^{13}C NMR (150 MHz, $CDCl_3$) δ 14.13, 21.25, 43.85, 70.50, 108.81, 124.90, 126.59, 126.65, 129.26, 129.40, 130.54, 131.17, 131.27, 132.59, 133.59, 138.17, 139.01, 155.72, 160.47, 170.59. Anal. Calcd for $C_{22}H_{20}Cl_3N_3OS$: C, 54.96; H, 4.19; N, 8.74. Found: C, 55.13; H, 4.26; N, 8.73.

1-{6-Chloro-4-(methylamino)-2-(methylsulfanyl)pyrimidin-5-yl}-3-(4-chlorophenyl)prop-2-en-1-ol (3f): a white solid; mp 193–196 °C (hexane/ CH_2Cl_2); IR (KBr) 3392, 1569 cm^{-1} ; 1H NMR (500 MHz, $DMSO-d_6$) δ 2.47 (s, 3H), 2.94 (d, $J = 4.6$ Hz, 3H), 5.71 (br s, 1H), 6.42–6.45 (m, 2H), 6.70 (d, $J = 16.1$ Hz, 1H), 7.30 (br s, 1H), 7.39 (d, $J = 8.6$ Hz, 2H), 7.51 (d, $J = 8.6$ Hz, 2H); ^{13}C NMR (125 MHz, $DMSO-d_6$) δ 13.45, 28.00, 68.88, 109.54, 128.26, 128.36, 128.61, 128.86, 132.08, 135.20, 153.90, 160.65, 168.76. Anal. Calcd for $C_{15}H_{15}Cl_2N_3OS$: C, 50.57; H, 4.24; N, 11.79. Found: C, 50.39; H, 4.26; N, 11.83.

1-{6-Chloro-2-(methylsulfanyl)-4-[(2-phenylethyl)amino]pyrimidin-5-yl}-3-(4-chlorophenyl)prop-2-en-1-ol (3g): a white solid; mp 130–133 °C (hexane/ CH_2Cl_2); IR (KBr) 3360, 1568 cm^{-1} ; 1H NMR (500

MHz, CDCl₃) δ 2.51 (s, 3H), 2.84–2.93 (m, 2H), 3.65–3.71 (m, 1H), 3.75–3.80 (m, 1H), 5.85 (dd, $J = 5.7$, 1.1 Hz, 1H), 6.13 (dd, $J = 16.0$, 5.7 Hz, 1H), 6.52 (d, $J = 16.0$ Hz, 1H), 6.82 (t, $J = 5.7$ Hz, 1H), 7.16–7.18 (m, 10H); ¹³C NMR (125 MHz, CDCl₃) δ 14.14, 35.23, 42.46, 70.45, 108.21, 126.48, 126.61, 127.88, 128.55, 128.70, 128.75, 129.99, 133.64, 134.54, 138.89, 155.26, 160.43, 170.43. Anal. Calcd for C₂₂H₂₁Cl₂N₃OS: C, 59.20; H, 4.74; N, 9.41. Found: C, 59.06; H, 4.89; N, 9.03.

1-{6-Chloro-4-(methylamino)-2-(methylsulfanyl)pyrimidin-5-yl}-3-(4-methoxyphenyl)prop-2-en-1-ol (3h): a yellow solid; mp 142–144 °C (hexane/CH₂Cl₂); IR (KBr) 3400, 3309, 1605, 1575 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 2.51 (s, 3H), 2.99 (d, $J = 5.2$ Hz, 3H), 3.30 (br, 1H), 3.80 (s, 3H), 5.89 (d, $J = 4.6$ Hz, 1H), 6.16 (dd, $J = 15.4$, 5.7 Hz, 1H), 6.59 (d, $J = 15.4$ Hz, 1H), 6.77 (d, $J = 4.6$ Hz, 1H), 6.84 (d, $J = 9.2$ Hz, 2H), 7.30 (d, $J = 9.2$ Hz, 2H); ¹³C NMR (125 MHz, CDCl₃) δ 14.07, 28.09, 55.29, 70.78, 108.73, 113.99, 123.80, 127.90, 128.82, 130.90, 155.08, 159.52, 161.16, 170.25. Anal. Calcd for C₁₆H₁₈ClN₃O₂S: C, 54.62; H, 5.16; N, 11.94. Found: C, 54.45; H, 5.38; N, 11.92.

1-{6-Chloro-2-(methylsulfanyl)-4-[(phenylmethyl)amino]pyrimidin-5-yl}-3-(4-methoxyphenyl)prop-2-en-1-ol (3i): a white solid; mp 118–120 °C (hexane/CH₂Cl₂); IR (KBr) 3426, 3350, 1607 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 2.44 (s, 3H), 2.91 (br, 1H), 3.81 (s, 3H), 4.58 (dd, $J = 15.4$, 5.7 Hz, 1H), 4.78 (dd, $J = 15.4$, 5.7 Hz, 1H), 5.94 (dd, $J = 5.2$, 1.1 Hz, 1H), 6.18 (dd, $J = 16.0$, 5.2 Hz, 1H), 6.60 (dd, $J = 16.0$, 1.1 Hz, 1H), 6.84 (d, $J = 9.2$ Hz, 2H), 7.11 (t, $J = 5.7$ Hz, 1H), 7.21–7.28 (m, 7H); ¹³C NMR (125 MHz, CDCl₃) δ 14.10, 44.98, 55.30, 70.64, 108.59, 113.99, 123.84, 127.21, 127.32, 127.91, 128.57, 128.75, 130.81, 138.47, 155.50, 159.54, 160.49, 170.44. Anal. Calcd for C₂₂H₂₂ClN₃O₂S: C, 61.75; H, 5.18; N, 9.82. Found: C, 61.37; H, 5.32; N, 9.88.

1-{6-Chloro-4-[(4-chlorophenylmethyl)amino]-2-(methylsulfanyl)pyrimidin-5-yl}-3-(4-methoxyphenyl)prop-2-en-1-ol (3j): a white solid; mp 132–134 °C (hexane/CH₂Cl₂); IR (KBr) 3384, 1608 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 2.42 (s, 3H), 3.11 (d, $J = 2.9$ Hz, 1H), 3.82 (s, 3H), 4.52 (dd, $J = 15.4$, 5.2 Hz, 1H), 4.76 (dd, $J = 15.4$, 6.3 Hz, 1H), 5.93–5.95 (m, 1H), 6.15 (dd, $J = 16.0$, 5.1 Hz, 1H), 6.57 (dd, $J = 16.0$, 1.1 Hz, 1H), 6.86 (d, $J = 9.2$ Hz, 2H), 7.12 (dd, $J = 6.3$, 5.2 Hz, 1H), 7.17 (s, 4H), 7.26 (d, $J = 9.2$ Hz, 2H); ¹³C NMR (125 MHz, CDCl₃) δ 14.10, 44.25, 55.31, 70.47, 108.71, 114.03, 123.73, 127.85, 128.62, 128.68 (two overlapped Cs), 130.70, 132.90, 137.02, 155.52, 159.56, 160.43, 170.43. Anal. Calcd for C₂₂H₂₁Cl₂N₃O₂S: C, 57.15; H, 4.58; N, 9.09. Found: C, 57.16; H, 4.63; N, 9.04.

1-[6-Chloro-4-(cyclopropylamino)-2-(methylsulfanyl)pyrimidin-5-yl]-3-(4-methoxyphenyl)prop-2-en-1-ol (3k): a colorless viscous oil; R_f 0.33 (AcOEt/hexane 1:5); IR (neat) 3339, 3209, 1608 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 0.45–0.51 (m, 2H), 0.77–0.80 (m, 2H), 2.53 (s, 3H), 2.84–2.87 (m, 1H), 3.15 (d, $J = 2.9$ Hz, 1H), 3.80 (s, 3H), 5.87 (d, $J = 5.7$ Hz, 1H), 6.10 (dd, $J = 16.0$, 5.7 Hz, 1H), 6.56 (dd, $J = 16.0$, 1.1 Hz, 1H), 6.84 (d, $J = 8.6$ Hz, 2H), 6.90 (d, $J = 2.9$ Hz, 1H), 7.28 (d, $J = 8.6$ Hz, 2H); ¹³C NMR

(125 MHz, CDCl₃) δ 7.00, 7.47, 14.09, 24.01, 55.27, 70.63, 108.67, 114.01, 123.78, 127.87, 128.82, 130.82, 155.21, 159.21, 161.85, 170.34. MR–MS (ESI). Calcd for C₁₈H₂₁ClN₃O₂S (M+H): 378.1043. Found: *m/z* 378.1032.

Typical Procedure for the Preparation of 2-[(Pyrimidin-2-yl)amino]acetonitriles (5).
2-({5-Chloro-4-[1-hydroxy-3-(4-methoxyphenyl)prop-2-enyl]-2-(methylsulfanyl)pyrimidin-2-yl}-amino)acetonitrile (5d). A mixture of **2d** (0.36 g, 1.0 mmol) and 2-aminoacetonitrile hydrochloride (94 mg, 1.0 mmol) in DMF (6 mL) containing Et₃N (0.20 g, 2.0 mmol) was stirred for 150 h at rt. The mixture was worked up as described for the preparation of **3a** and the residue was purified by column chromatography on SiO₂ (Et₂O/hexane 3:2) to give **5d** (0.20 g, 53%); a white solid; mp 151–154 °C (hexane/CH₂Cl₂); IR (KBr) 3336, 2241, 1608 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 2.56 (s, 3H), 3.32 (br s, 1H), 3.80 (s, 3H), 4.27 (dd, *J* = 17.2, 5.2 Hz, 1H), 4.40 (dd, *J* = 17.2, 6.3 Hz, 1H), 5.89 (br s, 1H), 6.14 (dd, *J* = 16.0, 6.3 Hz, 1H), 6.60 (d, *J* = 16.0 Hz, 1H), 6.84 (d, *J* = 8.6 Hz, 2H), 7.24 (dd, *J* = 6.3, 5.2 Hz, 1H), 7.27 (d, *J* = 8.6 Hz, 2H); ¹³C NMR (125 MHz, CDCl₃) δ 14.17, 29.42, 55.30, 70.78, 110.01, 114.04, 116.29, 123.15, 127.99, 128.46, 131.52, 156.17, 159.69, 159.89, 170.79. Anal. Calcd for C₁₇H₁₇ClN₄O₂S: C, 54.18; H, 4.55; N, 14.87. Found: C, 53.93; H, 4.61; N, 14.95.

2-({5-Chloro-4-[1-hydroxy-3-(4-methylphenyl)prop-2-enyl]-2-(methylsulfanyl)pyrimidin-2-yl}-amino)acetonitrile (5b): a pale-yellow solid; mp 163–165 °C (hexane/CH₂Cl₂); IR (KBr) 3332, 2242 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 2.33 (s, 3H), 2.56 (s, 3H), 3.45 (br s, 1H), 4.25 (dd, *J* = 17.2, 5.2 Hz, 1H), 4.39 (dd, *J* = 17.2, 6.9 Hz, 1H), 5.89 (d, *J* = 5.7 Hz, 1H), 6.22 (dd, *J* = 16.0, 5.7 Hz, 1H), 6.62 (d, *J* = 16.0 Hz, 1H), 7.12 (d, *J* = 8.0 Hz, 2H), 7.23–7.27 (m, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 14.17, 21.20, 29.42, 70.60, 109.95, 116.27, 124.34, 126.61, 129.34, 131.77, 132.93, 138.23, 156.11, 159.89, 170.78. Anal. Calcd for C₁₇H₁₇ClN₄OS: C, 56.58; H, 4.75; N, 15.53. Found: C, 56.22; H, 4.81; N, 15.30.

Typical Procedure for the Preparation of 7,8-Dihydropyrido[2,3-*d*]pyrimidine Derivatives (4) and (6).
8-Butyl-4-chloro-2-(methylsulfanyl)-7-phenyl-7,8-dihydropyrido[2,3-*d*]pyrimidine (4a). To a stirred solution of **3a** (0.38 g, 1.1 mmol) in THF (4 mL) containing Et₃N (0.21 g, 2.1 mmol) at 0 °C was added MsCl (0.12 g, 1.1 mmol) dropwise. After stirring was continued for 1 h, saturated aqueous NH₄Cl (15 mL) was added and the mixture was extracted with AcOEt (3 × 10 mL). The combined extracts were washed with brine (10 mL), dried (Na₂SO₄), and concentrated by evaporation. The residue was purified by column chromatography on SiO₂ to give **4a** (0.22 g, 64%); a yellow oil; *R_f* 0.46 (AcOEt/hexane 1:10); IR (neat) 1645, 1566 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 0.87 (t, *J* = 7.6 Hz, 3H), 1.21–1.31 (m, 2H), 1.35–1.42 (m, 1H), 1.54–1.62 (m, 1H), 2.48 (s, 3H), 2.82–2.88 (m, 1H), 3.89–3.95 (m, 1H), 5.40 (d, *J* = 3.8 Hz, 1H), 5.58 (dd, *J* = 9.9, 4.6 Hz, 1H), 6.52 (d, *J* = 9.9 Hz, 1H), 7.28–7.42 (m, 5H); ¹³C NMR (125 MHz, CDCl₃) δ 13.81, 14.14, 20.67, 28.31, 45.85, 64.05, 105.07, 118.00, 125.17, 126.73, 128.47, 129.06,

141.84, 152.87, 158.30, 170.11. MR–MS (EI). Calcd for C₁₈H₂₀ClN₃S (M): 345.1066. Found: *m/z* 345.1050. Anal. Calcd for C₁₈H₂₀ClN₃S: C, 62.51; H, 5.83; N, 12.15. Found: C, 62.49; H, 5.83; N, 12.03.

4-Chloro-2-(methylsulfanyl)-7-phenyl-8-(phenylmethyl)-7,8-dihydropyrido[2,3-*d*]pyrimidine (4b): a yellow solid; mp 153–155 °C (hexane/CH₂Cl₂); IR (KBr) 1649, 1564 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 2.45 (s, 3H), 3.62 (d, *J* = 15.3 Hz, 1H), 5.26 (d, *J* = 3.8 Hz, 1H), 5.55 (dd, *J* = 9.9, 3.8 Hz, 1H), 5.79 (d, *J* = 15.3 Hz, 1H), 6.55 (d, *J* = 9.9 Hz, 1H), 7.20–7.41 (m, 10H); ¹³C NMR (125 MHz, CDCl₃) δ 14.22, 47.38, 62.37, 105.06, 117.87, 125.36, 126.94, 127.62, 127.97, 128.59, 128.74, 129.16, 136.18, 141.05, 153.41, 158.61, 170.30. MR–MS (EI). Calcd for C₂₁H₁₈ClN₃S (M): 379.0910. Found: *m/z* 379.0892. Anal. Calcd for C₂₁H₁₈ClN₃S: C, 66.39; H, 4.78; N, 11.06. Found: C, 66.25; H, 4.87; N, 10.94.

4-Chloro-8-(2-methoxyethyl)-2-(methylsulfanyl)-7-phenyl-7,8-dihydropyrido[2,3-*d*]pyrimidine (4c): a yellow oil; *R_f* 0.38 (AcOEt/hexane 2:15); IR (neat) 1645, 1566 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 2.47 (s, 3H), 3.06–3.13 (m, 1H), 3.31 (s, 3H), 3.35–3.39 (m, 1H), 3.63–3.68 (m, 1H), 4.04–4.08 (m, 1H), 5.57–5.59 (m, 2H), 6.51 (dd, *J* = 11.5, 3.1 Hz, 1H), 7.28 (d, *J* = 7.6 Hz, 2H), 7.32 (t, *J* = 7.6 Hz, 1H), 7.38 (t, *J* = 7.6 Hz, 2H); ¹³C NMR (125 MHz, CDCl₃) δ 14.15, 45.47, 58.98, 65.22, 70.16, 105.44, 117.67, 125.70, 126.93, 128.46, 129.08, 141.75, 152.86, 158.34, 170.05. HR–MS (EI). Calcd for C₁₇H₁₈ClN₃OS (M): 347.0859. Found: *m/z* 347.0857. Anal. Calcd for C₁₇H₁₈ClN₃OS: C, 58.70; H, 5.22; N, 12.08. Found: C, 58.65; H, 5.23; N, 12.09.

4-Chloro-8-methyl-7-(4-methylphenyl)-2-(methylsulfanyl)-7,8-dihydropyrido[2,3-*d*]pyrimidine (4d): a yellow oil; *R_f* 0.37 (AcOEt/hexane 1:15); IR (neat) 1645, 1567 cm⁻¹; ¹H NMR (600 MHz, CDCl₃) δ 2.35 (s, 3H), 2.49 (s, 3H), 2.91 (s, 3H), 5.26 (dd, *J* = 4.3, 1.4 Hz, 1H), 5.57 (dd, *J* = 10.1, 4.3 Hz, 1H), 6.53 (dd, *J* = 10.4, 1.4 Hz, 1H), 7.15 (d, *J* = 8.1 Hz, 2H), 7.18 (d, *J* = 8.1 Hz, 2H); ¹³C NMR (150 MHz, CDCl₃) δ 14.18, 21.15, 33.90, 65.94, 105.22, 117.94, 125.42, 126.65, 129.78, 138.31, 138.45, 152.73, 158.52, 170.25. HR–MS (EI). Calcd for C₁₆H₁₆ClN₃S (M): 317.0753. Found: *m/z* 317.0748. Anal. Calcd for C₁₆H₁₆ClN₃S: C, 60.46; H, 5.07; N, 13.22. Found: C, 60.26; H, 5.12; N, 13.01.

4-Chloro-8-[(3,4-dichlorophenyl)methyl]-7-(4-methylphenyl)-2-(methylsulfanyl)-7,8-dihydropyrido[2,3-*d*]pyrimidine (4e): a pale-yellow amorphous powder; *R_f* 0.49 (AcOEt/hexane 1:15); IR (neat) 1646, 1566 cm⁻¹; ¹H NMR (600 MHz, CDCl₃) δ 2.36 (s, 3H), 2.44 (s, 3H), 3.75 (d, *J* = 15.5 Hz, 1H), 5.20 (dd, *J* = 4.3, 1.3 Hz, 1H), 5.51 (d, *J* = 15.5 Hz, 1H), 5.57 (dd, *J* = 10.0, 4.3 Hz, 1H), 6.56 (dd, *J* = 10.0, 1.3 Hz, 1H), 7.04 (dd, *J* = 8.2, 1.9 Hz, 1H), 7.11 (d, *J* = 8.0 Hz, 2H), 7.18 (d, *J* = 8.0 Hz, 2H), 7.24 (d, *J* = 1.9 Hz, 1H), 7.38 (d, *J* = 8.2 Hz, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 14.24, 21.17, 46.81, 62.80, 105.30, 117.82, 125.53, 126.92, 127.28, 129.83, 129.91, 130.65, 131.60, 132.75, 136.81, 137.83, 138.83, 153.56, 158.46, 170.39. HR–MS (ESI). Calcd for C₂₂H₁₉Cl₃N₃S (M+H): 462.0365. Found: *m/z* 462.0350. Anal. Calcd for C₂₂H₁₈Cl₃N₃S: C, 57.09; H, 3.92; N, 9.08. Found: C, 56.76; H, 4.05; N, 9.33.

4-Chloro-7-(4-chlorophenyl)-8-methyl-2-(methylsulfanyl)-7,8-dihydropyrido[2,3-*d*]pyrimidine (4f): a pale-yellow solid; mp 96–99 °C (hexane/CH₂Cl₂); IR (KBr) 1645, 1568 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 2.50 (s, 3H), 2.91 (s, 3H), 5.30 (dd, *J* = 4.6, 1.7 Hz, 1H), 5.55 (dd, *J* = 9.7, 4.6 Hz, 1H), 6.56 (dd, *J* = 9.7, 1.7 Hz, 1H), 7.22 (d, *J* = 8.6 Hz, 2H), 7.36 (d, *J* = 8.6 Hz, 2H); ¹³C NMR (125 MHz, CDCl₃) δ 14.17, 33.93, 65.55, 104.97, 118.45, 124.59, 128.03, 129.32, 134.40, 139.60, 152.99, 158.40, 170.49. HR-MS (EI). Calcd for C₁₅H₁₃Cl₂N₃S (M): 337.0207. Found: *m/z* 337.0195. Anal. Calcd for C₁₅H₁₃Cl₂N₃S: C, 53.26; H, 3.87; N, 12.42. Found: C, 53.17; H, 3.96; N, 12.34.

4-Chloro-7-(4-chlorophenyl)-2-(methylsulfanyl)-8-(2-phenylethyl)-7,8-dihydropyrido[2,3-*d*]pyrimidine (4g): a pale-yellow solid; mp 100–104 °C (hexane/CH₂Cl₂); IR (KBr) 1650, 1568 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 2.53 (s, 3H), 2.59–2.65 (m, 1H), 2.93–2.96 (m, 1H), 3.09–3.12 (m, 1H), 3.99–4.02 (m, 1H), 5.10 (dd, *J* = 4.6, 1.7 Hz, 1H), 5.45 (dd, *J* = 10.3, 4.6 Hz, 1H), 6.53 (dd, *J* = 10.3, 1.7 Hz, 1H), 7.11–7.36 (m, 9H); ¹³C NMR (125 MHz, CDCl₃) δ 14.25, 32.95, 48.39, 64.30, 105.02, 118.27, 124.65, 126.55, 128.28, 128.61, 128.72, 129.32, 134.47, 138.78, 140.23, 153.13, 158.08, 170.50. HR-MS (ESI). Calcd for C₂₂H₂₀Cl₂N₃S (M+H): 428.0755. Found: *m/z* 428.0752. Anal. Calcd for C₂₂H₁₉Cl₂N₃S: C, 61.68; H, 4.47; N, 9.81. Found: C, 61.40; H, 4.72; N, 9.70.

4-Chloro-7-(4-methoxyphenyl)-8-methyl-2-(methylsulfanyl)-7,8-dihydropyrido[2,3-*d*]pyrimidine (4h): a yellow oil; *R_f* 0.63 (AcOEt/hexane 1:2); IR (neat) 1645, 1608, 1567 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 2.49 (s, 3H), 2.90 (s, 3H), 3.81 (s, 3H), 5.25 (d, *J* = 4.0 Hz, 1H), 5.57 (dd, *J* = 9.7, 4.0 Hz, 1H), 6.55 (d, *J* = 9.7 Hz, 1H), 6.89 (d, *J* = 8.6 Hz, 2H), 7.19 (d, *J* = 8.6 Hz, 2H); ¹³C NMR (125 MHz, CDCl₃) δ 14.14, 33.76, 55.32, 65.52, 105.14, 114.36, 117.84, 125.38, 128.01, 133.42, 152.69, 158.34, 159.75, 170.20. HR-MS (EI). Calcd for C₁₆H₁₆ClN₃OS (M): 333.0703. Found: *m/z* 333.0693. Anal. Calcd for C₁₆H₁₆ClN₃OS: C, 61.68; H, 4.47; N, 9.81. Found: C, 57.32; H, 5.02; N, 12.51.

4-Chloro-7-(4-methoxyphenyl)-2-(methylsulfanyl)-8-(phenylmethyl)-7,8-dihydropyrido[2,3-*d*]pyrimidine (4i): a yellow oil; *R_f* 0.50 (AcOEt/hexane 2:15); IR (neat) 1645, 1608, 1563 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 2.44 (s, 3H), 3.64 (d, *J* = 14.9 Hz, 1H), 3.82 (s, 3H), 5.20 (d, *J* = 4.6 Hz, 1H), 5.53 (dd, *J* = 9.7, 4.6 Hz, 1H), 5.76 (d, *J* = 14.9 Hz, 1H), 6.55 (d, *J* = 9.7 Hz, 1H), 6.90 (d, *J* = 8.6 Hz, 2H), 7.17 (d, *J* = 8.6 Hz, 2H), 7.21 (d, *J* = 7.4 Hz, 2H), 7.29 (t, *J* = 7.4 Hz, 1H), 7.34 (t, *J* = 7.4 Hz, 2H); ¹³C NMR (125 MHz, CDCl₃) δ 14.21, 47.20, 55.34, 61.70, 105.06, 114.41, 117.64, 125.57, 127.58, 127.96, 128.32, 128.71, 133.30, 136.23, 153.33, 158.47, 159.80, 170.23. HR-MS (EI). Calcd for C₂₂H₂₀ClN₃OS (M): 409.1016. Found: *m/z* 409.1014. Anal. Calcd for C₂₂H₂₀ClN₃OS: C, 64.46; H, 4.92; N, 10.25. Found: C, 64.39; H, 5.01; N, 10.28.

4-Chloro-8-(4-chlorophenylmethyl)-7-(4-methoxyphenyl)-2-(methylsulfanyl)-7,8-dihydropyrido[2,3-*d*]pyrimidine (4j): a white solid; mp 101–104 °C (hexane/CH₂Cl₂); IR (KBr) 1649, 1610, 1567 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 2.43 (s, 3H), 3.67 (d, *J* = 15.5 Hz, 1H), 3.82 (s, 3H), 5.17 (d, *J* = 4.0 Hz, 1H),

5.54 (dd, $J = 9.7, 4.0$ Hz, 1H), 5.64 (d, $J = 15.5$ Hz, 1H), 6.55 (d, $J = 9.7$ Hz, 1H), 6.89 (d, $J = 8.6$ Hz, 2H), 7.14 (d, $J = 8.0$ Hz, 2H), 7.15 (d, $J = 8.0$ Hz, 2H), 7.29 (d, $J = 8.6$ Hz, 2H); ^{13}C NMR (125 MHz, CDCl_3) δ 14.22, 46.72, 55.36, 61.91, 105.11, 114.45, 117.65, 125.55, 128.28, 128.86, 129.31, 130.06, 133.35, 134.79, 153.41, 158.37, 159.85, 170.26. Anal. Calcd for $\text{C}_{22}\text{H}_{19}\text{Cl}_2\text{N}_3\text{OS}$: C, 59.46; H, 4.31; N, 9.46. Found: C, 59.30; H, 4.37; N, 9.32.

4-Chloro-8-cyclopropyl-7-(4-methoxyphenyl)-2-(methylsulfonyl)-7,8-dihydropyrido[2,3-*d*]pyrimidine (4k): a yellow oil; R_f 0.45 (AcOEt/hexane 1:6); IR (neat) 1641, 1608, 1563 cm^{-1} ; ^1H NMR (500 MHz, CDCl_3) δ 0.64–0.67 (m, 1H), 0.71–0.74 (m, 1H), 0.77–0.81 (m, 1H), 2.27–2.30 (m, 1H), 1.03–1.06 (m, 1H), 2.50 (s, 3H), 3.79 (s, 3H), 5.22 (d, $J = 4.6$ Hz, 1H), 5.70 (dd, $J = 9.7, 5.2$ Hz, 1H), 5.61 (d, $J = 9.7$ Hz, 1H), 6.87 (d, $J = 8.6$ Hz, 2H), 7.21 (d, $J = 8.6$ Hz, 2H); ^{13}C NMR (125 MHz, CDCl_3) δ 6.46, 11.15, 14.17, 28.83, 55.30, 62.85, 106.63, 114.25, 118.14, 126.16, 128.10, 132.70, 152.95, 159.75 (two overlapped Cs), 170.03. HR-MS (EI). Calcd for $\text{C}_{18}\text{H}_{18}\text{ClN}_3\text{OS}$ (M): 359.0859. Found: m/z 359.0842. Anal. Calcd for $\text{C}_{18}\text{H}_{18}\text{ClN}_3\text{OS}$: C, 60.08; H, 5.04; N, 11.68. Found: C, 60.12; H, 5.34; N, 11.67.

[4-Chloro-7-(4-methylphenyl)-2-(methylsulfonyl)-7,8-dihydropyrido[2,3-*d*]pyrimidin-8-yl]acetonitrile (6b): a white solid; mp 172–175 °C (hexane/ CH_2Cl_2); IR (KBr) 2248, 1637, 1564 cm^{-1} ; ^1H NMR (500 MHz, CDCl_3) δ 2.37 (s, 3H), 2.52 (s, 3H), 3.75 (d, $J = 17.8$ Hz, 1H), 4.86 (d, $J = 17.8$ Hz, 1H), 5.50 (dd, $J = 4.0, 1.7$ Hz, 1H), 5.65 (dd, $J = 10.3, 4.0$ Hz, 1H), 6.59 (dd, $J = 10.3, 1.7$ Hz, 1H), 7.23 (s, 4H); ^{13}C NMR (125 MHz, CDCl_3) δ 14.24, 21.18, 33.29, 63.99, 105.76, 114.72, 117.67, 125.47, 127.17, 130.15, 136.25, 139.50, 153.75, 157.30, 170.70. HR-MS (EI). Calcd for $\text{C}_{17}\text{H}_{15}\text{ClN}_4\text{S}$ (M): 342.0706. Found: m/z 342.0706. Anal. Calcd for $\text{C}_{17}\text{H}_{15}\text{ClN}_4\text{S}$: C, 59.56; H, 4.41; N, 16.34. Found: C, 59.59; H, 4.48; N, 16.18.

[4-Chloro-7-(4-methoxyphenyl)-2-(methylsulfonyl)-7,8-dihydropyrido[2,3-*d*]pyrimidin-8-yl]acetonitrile (6d): a pale-yellow solid; mp 156–158 °C (hexane/ CH_2Cl_2); IR (KBr) 2245, 1641, 1612, 1562 cm^{-1} ; ^1H NMR (500 MHz, CDCl_3) δ 2.52 (s, 3H), 3.77 (d, $J = 17.2$ Hz, 1H), 4.86 (d, $J = 17.2$ Hz, 1H), 3.82 (s, 3H), 5.48 (d, $J = 1.7$ Hz, 1H), 5.65 (dd, $J = 10.3, 4.0$ Hz, 1H), 6.59 (dd, $J = 10.3, 1.7$ Hz, 1H), 6.93 (d, $J = 8.6$ Hz, 2H), 7.27 (d, $J = 8.6$ Hz, 2H); ^{13}C NMR (125 MHz, CDCl_3) δ 14.25, 33.21, 55.37, 63.63, 105.73, 114.73, 114.76, 117.63, 125.52, 128.63, 131.27, 153.75, 157.21, 160.40, 170.70. HR-MS (EI). Calcd for $\text{C}_{17}\text{H}_{15}\text{ClN}_4\text{OS}$ (M): 358.0655. Found: m/z 358.0651. Anal. Calcd for $\text{C}_{17}\text{H}_{15}\text{ClN}_4\text{OS}$: C, 56.90; H, 4.21; N, 15.61. Found: C, 56.80; H, 4.18; N, 15.49.

ACKNOWLEDGEMENTS

We are indebted to Mrs. Miyuki Tanmatsu of this university for recording mass spectra and performing combustion analyses.

REFERENCES

- (a) J. L. Adams, J. C. Boehm, R. Hall, Q. Jin, D. J. Silva, and J. J. Taggart, *PCT Int. Appl.*, 2002, WO 2002059083 (*Chem. Abstr.*, 2002, **137**, 140533); (b) M. R. Barvian, R. J. Booth, J. Quin, III, J. T. Repine, D. J. Sheehan, P. L. Toogood, S. N. Vanderwel, N. Scott, and H. Zhou, *PCT Int. Appl.*, 2003, WO 2003062236 (*Chem. Abstr.*, 2003, **139**, 149646); (c) T. Shibata, N. J. Buurma, J. A. Brazier, P. Thompson, I. Haq, and D. M. Williams, *Chem. Commun.*, 2006, **3516**; (d) C. A. Buhr, W. Bajjalleh, A. A. Joshi, K. Lara, S. Ma, C. K. Sunghoon, L. Wang, and B. K. S. Yeung, *PCT Int. Appl.*, 2008, WO 2008127678 (*Chem. Abstr.*, 2008, **149**, 471497); (e) F. Brookfield, F. Eustache, M. P. Dillon, D. M. Goldstein, L. Gong, X. Han, J. H. Hogg, J. Park, D. C. Reuter, and E. B. Sjogren, *U.S. Pat. Appl. Publ.*, 2009, 20090270389 (*Chem. Abstr.*, 2009, **151**, 491149); (f) E. P. Reddy and M. V. R. Reddy, *PCT Int. Appl.*, 2012, WO 2012018540 (*Chem. Abstr.*, 2012, **156**, 276580); (g) H. Kawai, D. Murata, and Y. Suzumura, *PCT Int. Appl.*, 2013, WO 2013115265 (*Chem. Abstr.*, 2013, **159**, 333537); (h) M. V. R. Reddy, B. Akula, S. C. Cosenza, S. Athuluridivakar, M. R. Mallireddigari, V. R. Pallela, V. K. Billa, D. R. C. V. Subbaiah, E. V. Bharathi, R. V.-D. Carpio, A. Padgaonkar, and S. J. Baker, *J. Med. Chem.*, 2014, **57**, 578; (i) J. S. S. Rountree, C. R. O'Dowd, R. Colin, F. Burkamp, and M. P. Bell, *PCT Int. Appl.*, 2015, WO 2015019037 (*Chem. Abstr.*, 2015, **162**, 300245).
- (a) L. Zhao, F. Liang, X. Bi, S. Sun, and Q. Liu, *J. Org. Chem.*, 2006, **71**, 1094; (b) A. V. Komkov, M. A. Prezent, A. V. Ignatenko, I. P. Yakovlev, and V. A. Dorokhov, *Russ. Chem. Bull.*, 2006, **55**, 2085.
- (a) K. Kobayashi, T. Suzuki, T. Kozuki, N. Matsumoto, H. Hiyoshi, and K. Umezu, *Heterocycles*, 2012, **85**, 1405; (b) K. Kobayashi, T. Suzuki, A. Imaoka, H. Hiyoshi, and K. Umezu, *Heterocycles*, 2013, **87**, 885; (c) K. Kobayashi, M. Kuroda, N. Tanaka, Y. Yokoi, A. Kobayashi, H. Hiyoshi, and K. Umezu, *Heterocycles*, 2014, **89**, 1933; (d) K. Kobayashi, S. Yuba, A. Taniguchi, H. Inouchi, H. Hiyoshi, and K. Umezu, *Heterocycles*, 2014, **89**, 2611; (e) K. Kobayashi, K. Nakazawa, S. Yuba, H. Hiyoshi, and K. Umezu, *Heterocycles*, 2015, **90**, 216; (f) K. Kobayashi, R. Ono, S. Yuba, H. Hiyoshi, and K. Umezu, *Heterocycles*, 2015, **91**, 1177; (g) K. Kobayashi, R. Ono, K. Ishitobi, Y. Chikazawa, H. Hiyoshi, and K. Umezu, *Heterocycles*, 2016, **92**, 260; (h) K. Kobayashi, D. Fujiwara, Y. Shigemura, H. Hiyoshi, and K. Umezu, *Heterocycles*, 2017, **94**, 140.